+

WO2006067392A3 - Indole derivatives for the treatment of tuberculosis - Google Patents

Indole derivatives for the treatment of tuberculosis Download PDF

Info

Publication number
WO2006067392A3
WO2006067392A3 PCT/GB2005/004876 GB2005004876W WO2006067392A3 WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3 GB 2005004876 W GB2005004876 W GB 2005004876W WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tuberculosis
indole derivatives
medicament
manufacture
Prior art date
Application number
PCT/GB2005/004876
Other languages
French (fr)
Other versions
WO2006067392A2 (en
Inventor
Vijaykumar Hulikal
Ranga Rao Kajipalya Rangan Rao
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Vijaykumar Hulikal
Ranga Rao Kajipalya Rangan Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Vijaykumar Hulikal, Ranga Rao Kajipalya Rangan Rao filed Critical Astrazeneca Ab
Priority to EP05818623A priority Critical patent/EP1904487A2/en
Priority to JP2007547617A priority patent/JP2008525394A/en
Publication of WO2006067392A2 publication Critical patent/WO2006067392A2/en
Publication of WO2006067392A3 publication Critical patent/WO2006067392A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The use of a compound of the formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof in the manufacture of a medicament for the treatment of Mycobacterium tuberculosis (M.tb).
PCT/GB2005/004876 2004-12-23 2005-12-16 Indole derivatives for the treatment of tuberculosis WO2006067392A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05818623A EP1904487A2 (en) 2004-12-23 2005-12-16 Indole derivatives for the treatment of tuberculosis
JP2007547617A JP2008525394A (en) 2004-12-23 2005-12-16 Compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428173.9A GB0428173D0 (en) 2004-12-23 2004-12-23 Compounds
GB0428173.9 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006067392A2 WO2006067392A2 (en) 2006-06-29
WO2006067392A3 true WO2006067392A3 (en) 2007-03-08

Family

ID=34113122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004876 WO2006067392A2 (en) 2004-12-23 2005-12-16 Indole derivatives for the treatment of tuberculosis

Country Status (5)

Country Link
EP (1) EP1904487A2 (en)
JP (1) JP2008525394A (en)
CN (1) CN101087781A (en)
GB (1) GB0428173D0 (en)
WO (1) WO2006067392A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314732B2 (en) 2000-02-17 2008-01-01 Tfk Inc. Drug and manufacturing method of same
FR2967672B1 (en) * 2010-11-22 2012-12-28 Sanofi Aventis NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF
WO2013055674A1 (en) * 2011-10-10 2013-04-18 The University Of Toledo Method for treating infections
CA2881351A1 (en) * 2012-09-07 2014-03-13 Novartis Ag Indole carboxamide derivatives and uses thereof
SG11201702817SA (en) 2014-10-06 2017-05-30 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3037986C (en) 2016-09-30 2024-03-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
GEP20247634B (en) 2016-12-09 2024-06-25 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (en) 2017-07-17 2020-05-27 Vertex Pharma CYSTIC FIBROSIS TREATMENT METHODS
JP7121794B2 (en) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド Process for preparing pyrrolidine compounds
WO2019046465A2 (en) * 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey Therapeutic indoles
US11186549B2 (en) 2017-08-29 2021-11-30 Rutgers, The State University Of New Jersey Therapeutic indazoles
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
JP7245834B2 (en) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド A process for creating modulators of cystic fibrosis transmembrane conductance regulators
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP4149459A4 (en) * 2020-05-12 2024-05-22 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02165131A (en) * 1988-12-20 1990-06-26 Konica Corp Silver halide photographic sensitive material restrained from occurrence of fog
EP0791582A1 (en) * 1995-08-04 1997-08-27 Otsuka Kagaku Kabushiki Kaisha Indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient
WO1999007351A2 (en) * 1997-08-07 1999-02-18 Zeneca Limited Indole derivatives and their use as mcp-1 antagonists
WO1999033800A1 (en) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors or factor xa
WO2000046195A1 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Anti-inflammatory indole derivatives
US6352958B1 (en) * 1997-02-26 2002-03-05 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02165131A (en) * 1988-12-20 1990-06-26 Konica Corp Silver halide photographic sensitive material restrained from occurrence of fog
EP0791582A1 (en) * 1995-08-04 1997-08-27 Otsuka Kagaku Kabushiki Kaisha Indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient
US6352958B1 (en) * 1997-02-26 2002-03-05 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
WO1999007351A2 (en) * 1997-08-07 1999-02-18 Zeneca Limited Indole derivatives and their use as mcp-1 antagonists
US6441004B1 (en) * 1997-08-07 2002-08-27 Zeneca Limited Monocyte chemoattractant protein-1 inhibitor compounds
WO1999033800A1 (en) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors or factor xa
WO2000046195A1 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Anti-inflammatory indole derivatives
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERTHOLD H ET AL: "Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria.", JOURNAL OF PHARMACOLOGICAL METHODS., vol. 24, no. 2, September 1990 (1990-09-01), pages 121 - 135, XP002393947, ISSN: 0160-5402 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, LEE JENG-JONG ET AL: "Catalysis of decarboxylation of 6-nitrobenzisoxazole-3-carboxylate by cationic polymer colloids", XP002393946, Database accession no. PREV199396083201 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 58, no. 15, 1993, pages 4070 - 4077, ISSN: 0022-3263 *
KETTLE JASON G ET AL: "N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 14, no. 2, 19 January 2004 (2004-01-19), pages 405 - 408, XP002393948, ISSN: 0960-894X *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 422 (P - 1104) 12 September 1990 (1990-09-12) *

Also Published As

Publication number Publication date
GB0428173D0 (en) 2005-01-26
JP2008525394A (en) 2008-07-17
EP1904487A2 (en) 2008-04-02
CN101087781A (en) 2007-12-12
WO2006067392A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
WO2006067392A3 (en) Indole derivatives for the treatment of tuberculosis
WO2009054479A1 (en) Spiro-ring compound and use thereof for medical purposes
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2008115516A3 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2007087431A3 (en) Sublingual fentanyl spray
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
WO2007117465A3 (en) Indazole compounds
WO2007135527A3 (en) Benzimidazolyl compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2007061737A3 (en) FUSED BICYCLIC mTOR INHIBITORS
IL180916A0 (en) Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
WO2007084728A3 (en) 2-imino-benzimidazoles
MX2009006742A (en) Novel compounds.
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2008006795A3 (en) Indole compounds
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
EP1714961A4 (en) Indazole compound and pharmaceutical use thereof
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2007112913A3 (en) Benzimidazole derivatives
WO2008093838A1 (en) Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
WO2008004100A3 (en) Therapeutic compounds
MX2008002063A (en) Pyrazolone derivatives for the treatment of tuberculosis.
WO2005023188A3 (en) Compounds and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005818623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007547617

Country of ref document: JP

Ref document number: 200580044401.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05818623

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2005818623

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载